Myopia
Drug research and approvals for myopia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 17, 2026, 122 studies of myopia are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and the EU has 2 authorised medicines for it.
- Recruiting worldwide: 122
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 2
Recruiting Now
Newest start dates first, of 122 recruiting on ClinicalTrials.gov ↗- Evaluation of Two Monthly Silicone Hydrogel Multifocal Toric in Soft Contact Lens WearersNCT07829419 · Not applicable · CooperVision International Limited (CVIL) · starts Nov 2, 2026
- Comparison of Hand Eye Coordination and Sports Vision Performance in Dual-Focus Multifocal Contact Lenses and Habitual…NCT07840209 · Not applicable · Ohio State University · starts Oct 1, 2026
- Managing Premyopia in Chinese Children Using Artificial Intelligence Assisted Defocus Incorporated Multiple Segments…NCT07765550 · Not applicable · Shanghai Eye Disease Prevention and Treatment Center · starts Sep 12, 2026
- Screening for Hyperopic Reserve in KindergartenNCT07851532 · Not reported · Beijing Tongren Hospital · starts Sep 1, 2026
- Myopia Control Using Novel Soft Contact LensesNCT07547085 · Not applicable · The Hong Kong Polytechnic University · starts Aug 26, 2026
- Evaluation of Orthokeratology Lenses With a 5MM Optic Zone DiameterNCT07751172 · Not applicable · CooperVision International Limited (CVIL) · starts Aug 14, 2026
- Targeted Lens Intervention for Myopic Anisometropia in ChildrenNCT07533149 · Not applicable · Essilor International · starts Aug 13, 2026
- SMILE Surgery in One Eye Compared to Ray Tracing-guided LASIK Surgery in the Fellow EyeNCT07721714 · Phase 4 · Stanford University · starts Aug 5, 2026
- Assessing the Impact of Streetscape Exposure on Children's PerceptionNCT07761949 · Not reported · Zhongshan Ophthalmic Center, Sun Yat-sen University · starts Jul 2, 2026
- A RCT of Spectacles With Aspherical Lenslets or 0.05% Atropine for Myopia ControlNCT07095894 · Phase 3 · Jaeb Center for Health Research · starts Jul 1, 2026
Drug Pipeline
4 in phase 3, 2 in phase 2, 4 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition- Atropine
- Phase 3 Muscarinic acetylcholine receptor M3 antagonist
- Acetaminophen
- Phase 3 Cyclooxygenase inhibitor
- Codeine
- Phase 3 Opioid receptors; mu/kappa/delta agonist
- Bevacizumab
- Phase 3 Vascular endothelial growth factor A inhibitor
- Riboflavin
- Phase 2
- 7-METHYLXANTHINE
- Phase 2
- Mitomycin
- Phase 1 DNA inhibitor
- Cyclopentolate
- Phase 1 Muscarinic acetylcholine receptor M3 antagonist
- Ranibizumab
- Phase 1 Vascular endothelial growth factor A inhibitor
- Pilocarpine
- Early phase 1 Muscarinic acetylcholine receptor M3 agonist
How Its Trials Ended
812 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 71 whose ending is known, 52% met their primary endpoint, 4% missed it and 44% stopped early.
- Completed, result not reported44154%
- Ongoing17722%
- Status unknown12315%
- Met its primary endpoint375%
- Stopped: other or unclear202%
- Stopped: enrollment or feasibility40%
- Missed its primary endpoint30%
- Stopped: sponsor or business decision30%
- Stopped: lack of efficacy20%
- Stopped: safety10%
- Stopped: funding10%
Medicines Authorised in the EU
Newest first| Jun 2, 2025 | RyjuneaAtropine sulfate | Santen Oy | EMA ↗ |
| Jul 27, 2000 | VisudyneVerteporfin | CHEPLAPHARM Arzneimittel GmbH | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA